Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly low-dose versus every-3-weeks high-dose cisplatin in sarcopenic head and neck cancer patients receiving primary chemoradiation
NL-OMON60131Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cisplatin in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Compliance rate to proposed cisplatin scheme. Started Jan 2022; status: active, not recruiting.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NL-OMON60131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60131.